New hope for tough blood cancers? early trial of CG009301 begins

NCT ID NCT07347171

Recruiting now Disease control Sponsor: Cullgen (Shanghai),Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called CG009301 in adults with blood cancers like leukemia that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help. About 45 participants will receive the drug by IV infusion for 7 days in a row every 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CG009301 (a drug given by IV infusion once daily for 7 days every 28 days)
What this could lead to: If it works, this could point toward a new treatment option for people with blood cancers that have not responded to standard therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, so it is uncertain if the drug will be effective. Side effects and risks are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML AML (ACUTE MYELOGENOUS LEUKEMIA) LEUKEMIA MDS MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Locations

The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, China
The Haematology Hospital of the Chinese Academy of Medical Sciences
RECRUITING

Tianjin, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.